Breakthrough Signals for Pediatric IBD Treatment In a retrospective, single-center study presented in Las Vegas, researchers reported that upadacitinib (Rinvoq) provided durable clinical benefit over a full year for children and adolescents with inflammatory bowel disease (IBD). The study, which evaluated 48 patients with Crohn’s disease (CD) or ulcerative colitis (UC), adds to a growing…